1737-43-5

Usage

Uses

Used in Pharmaceutical Industry:
N1-Ethyl-4-fluorobenzene-1,2-diaMine is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of molecules with specific biological activities. The presence of the fluorine atom and the ethyl group on the molecule allows for the creation of drugs with tailored properties, such as improved pharmacokinetics, selectivity, and potency.
Used in Agrochemical Industry:
In the agrochemical sector, N1-Ethyl-4-fluorobenzene-1,2-diaMine serves as an intermediate in the production of agrochemicals, potentially enhancing the effectiveness of pesticides, herbicides, and other crop protection agents. Its structural features can be leveraged to design molecules with increased stability, selectivity, and reduced environmental impact.
Used in Organic Synthesis:
N1-Ethyl-4-fluorobenzene-1,2-diaMine is utilized as a building block in organic synthesis for the preparation of more complex organic compounds. Its unique structure allows chemists to create a variety of molecules with different functional groups and properties, expanding the scope of chemical research and development.
Used in Materials Science:
In materials science, N1-Ethyl-4-fluorobenzene-1,2-diaMine may find applications in the development of new materials with specific properties, such as improved thermal stability, electrical conductivity, or optical characteristics. Its incorporation into polymers, coatings, or other materials can lead to advancements in various industries, including electronics, automotive, and aerospace.

Upstream product

• 364-74-9 1,4-difluoro-2-nitrobenzene 
• 774-22-1 4-Fluor-2-nitro-N-ethyl-anilin 

Downstream Products

• 334829-55-9 1-ethyl-5-fluoro-1,3-dihydro-2H-benzimidazol-2-one 

Relevant academic research and scientific papers

2-aminobenzimidazoles for leishmaniasis: From initial hit discovery to in vivo profiling

Leishmaniasis is a major infectious disease with hundreds of thousands of new cases and over 20,000 deaths each year. The current drugs to treat this life-threatening infection have several drawbacks such as toxicity and long treatment regimens. A library of 1.8 million compounds, from which the hits reported here are publicly available, was screened against Leishmania infantum as part of an optimization program; a compound was found with a 2-aminobenzimidazole functionality presenting moderate potency, low metabolic stability and high lipophilicity. Several rounds of synthesis were performed to incorporate chemical groups capable of reducing lipophilicity and clearance, leading to the identification of compounds that are active against different parasite strains and have improved in vitro proper-ties. As a result of this optimization program, a group of compounds was further tested in anticipation of in vivo evaluation. In vivo tests were carried out with compounds 29 (L. infantum IC50: 4.1 μM) and 39 (L. infantum IC50: 0.5 μM) in an acute L. infantum VL mouse model, which showed problems of poor exposure and lack of efficacy, despite the good in vitro potency.

1- Or 3-(3-amino-2-hydroxy-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2- ones: Potent, selective, and orally efficacious norepinephrine reuptake inhibitors

Sequential structural modifications of the aryloxypropanamine template (e.g., atomoxetine, 2) led to a novel series of 1-(3-amino-2-hydroxy-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones as selective norepinephrine reuptake inhibitors (NRIs). In general, this series of compounds potently blocked the human norepinephrine transporter (hNET) while exhibiting selectivity at hNET against both the human serotonin (hSERT) and dopamine transporters (hDAT). Numerous compounds (e.g., 19-22) had low nonamolar hNET potency with IC 50 values of 7-10 nM and excellent selectivity (>500 fold) at hNET over hSERT and hDAT. Several compounds, such as 20 and 22, were tested in a telemetric rat model of ovariectomized-induced thermoregulatory dysfunction and were efficacious at oral doses of 3 mg/kg in reducing the tail skin temperature. In addition, compound 20 was also studied in the rat hot plate and spinal nerve ligation (SNL) models of acute and neuropathic pain, respectively, and was orally efficacious at doses of 3-10 mg/kg.